Metagenomi
MGX

$4.47

4.28%

Market Cap: 167M

About: Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).

Employees: 236

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 10 analysts

0

News positive %

of 5 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

13,298,462,300% more capital invested

Capital invested by funds: $0 [Q4 2023] → $133M (+$133M) [Q1 2024]

4,800% more funds holding

Funds holding: 0 [Q4 2023] → 48 (+48) [Q1 2024]

4,800% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 0

100% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 1 (+1) [Q1 2024]

33.7% more ownership

Funds ownership: 0% [Q4 2023] → 33.7% (+33.7%) [Q1 2024]

See Fund Rankings

Research analyst outlook

10 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

34%

upside

Avg. target

$16.40

267%

upside

High target

$25

459%

upside

10 analyst ratings

9 positive

90%

1 neutral

10%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor	124%upside $10	Buy Reiterated	15 Jul 2024
HC Wainwright & Co. Mitchell Kapoor	124%upside $10	Buy Reiterated	15 May 2024
HC Wainwright & Co. Mitchell Kapoor	124%upside $10	Buy Initiated	7 May 2024
JP Morgan Brian Cheng	34%upside $6	Neutral Downgraded	2 May 2024
Chardan Capital Geulah Livshits	370%upside $21	Buy Maintained	28 Mar 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about MGX published over the past 30 days

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. is Investigating Metagenomi, Inc. on Behalf of Metagenomi Stockholders and Encourages Investors to Contact the Firm

NEW YORK, July 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of Metagenomi stockholders. Our investigation concerns whether Metagenomi has violated the federal securities laws and/or engaged in other unlawful business practices.

METAGENOMI ALERT: Bragar Eagel & Squire, P.C. is Investigating Metagenomi, Inc. on Behalf of Metagenomi Stockholders and Encourages Investors to Contact the Firm

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Metagenomi investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Metagenomi, Inc. (MGX)

NEW YORK--(BUSINESS WIRE)---- $MGX #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX). The investigation concerns whether Metagenomi and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Metagenomi, Inc. (MGX)

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) investors concerning the Company's possible violations of federal securities laws. On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25 million shares at $15 per share. However, on May 1, 2024, less than three months after the IPO, Metagenomi announced that it and Moderna had “m.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQ: MGX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On February 12, 2024, Metagenomi conducted its initial public offering (“IPO”), selling approximately 6.25 million shares at $15 per share. However, on May 1, 2024, less than.

The Law Offices of Frank R. Cruz Announces Investigation of Metagenomi, Inc. (MGX) on Behalf of Investors

Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference

EMERYVILLE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that Metagenomi CEO and Founder, Brian C. Thomas, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 11:30 a.m. Eastern Time. The Company will also participate in one-on-one investor meetings at the conference taking place June 5-6.

Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

Late breaking presentation at World Federation of Hemophilia (WFH) World Congress on investigational development program in Hemophilia A; development candidate nomination anticipated in mid-year 2024; 12-month non-human primate durability data expected in 2H 2024

Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.

3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

Enhances strategic flexibility and control of key gene editing technologies and programs Enhances strategic flexibility and control of key gene editing technologies and programs

Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems

Metagenomi to Present at Upcoming Scientific Meetings

- Oral Presentation at World Federation of Hemophilia (WFH) World Congress, April 23, 2024 - Two Posters at American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, May 8 & 9, 2024 EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: a late breaking oral presentation at The World Federation of Hemophilia (WFH) World Congress, taking place April 21 – 24, 2024 in Madrid, Spain and two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Metagenomi to Present at Upcoming Scientific Meetings

See News Rankings